|
Dear Colleague,
We are very pleased to announce to you the “International Workshop on Neurofibromatosis Type 2: State of the Art”, which we are organizing in Paris, at Hôtel Le Meridien Etoile, during September, from the 7th to the 9th 2006.
We would like to promote NF2 experts meeting in order to develop a multidisciplinary approach and future developments.
Therefore, this international workshop will have three main objectives:
· Improve our understanding on NF2.
· Acquire the relevant knowledge on :
o Genetic and clinical diagnostic for NF2.
o Management of NF2 patients.
o Treatment of vestibular schwannoma and others tumours.
o Auditory rehabilitation: auditory brainstem implant (ABI) and other methods.
Stimulate NF2 genetic research in order to develop NF2 therapies in the near future.
In order to achieve these objectives, the workshop will only include main plenary sessions, and a poster exhibition.
Thus, with you, during these three days, we will establish “the State of the Art” of NF2 and will elaborate NF2 Guidelines that will be published for all the clinicians who are involved in NF2 management.
You could have more information on the workshop if you visit the website: http://nf2-workshop.inserm-u674.net
Kind regards
Michel KALAMARIDES, M.D. Olivier STERKERS, M.D., Ph.D.
Neurosurgery Department Professor and Chairman of ENT Department
Beaujon Hospital, France Beaujon Hospital, France
D Gareth R EVANS, M.D., Ph.D. Marco GIOVANNINI, M.D., Ph.D.
Department of Medical Genetics Director of Research, Inserm
St Mary’s Hospital, Manchester, UK Paris, France
Looking forward to welcoming you in Paris,
Suzanne Mullarkey
Director of Administration
NexGenix Pharmaceuticals Holdings, Inc
152 West 57th Street, Suite 11B
New York, NY 10019
Phone: (212) 974-3006
Fax: (212) 974-1042
smullarkey@nexgenixpharm.com
|